COMMUNIQUÉS West-GlobeNewswire

Zealand Pharma to participate in the Jefferies Global Healthcare Conference
27/05/2026
Press release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company [...]
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
27/05/2026
WALTHAM, Mass. and BOULDER, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today [...]
Southern California Reproductive Center Joins Nucleus IVF+ Network as Patient Demand Accelerates
27/05/2026
The move brings Genetic Optimization to one of the most sought-after fertility clinics in the U.S., following Nucleus’ rapid global expansion across 160+ clinics NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Nucleus [...]
BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations
27/05/2026
Roy brings defense leadership, digital infrastructure, and large scale commercialization experience as BiomX advances its defense and security transition NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. ( [...]
Health Coalition to provide details re. giant march Thursday to demand Doug Ford stop his unprecedented privatization of our public hospital services
27/05/2026
Entire train cars with people coming in to join thousands in Toronto for profits TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- The Ontario Health Coalition will hold a media availability ahead of a giant march and rallies [...]
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
27/05/2026
Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics [...]
Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
27/05/2026
Company also advances fibrin/VEGF bispecific antibody THN622, a potential new standard of care for retinal neurodegeneration SACRAMENTO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage [...]
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
27/05/2026
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for [...]
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
27/05/2026
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical- [...]
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026
Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant [...]
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
27/05/2026
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
Medline announces participation in upcoming investor conferences
27/05/2026
NORTHFIELD, Ill., May 27, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that members of the executive leadership team will be participating in the following investor conferences. Mike [...]
HNL Lab Medicine Receives Accreditation from the College of American Pathologists
27/05/2026
ALLENTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) following a recent on-site inspection [...]
Transforming Rural Health Care Through a First-of-its-Kind Collaborative
27/05/2026
A study designed to address rural pharmacy deserts by bringing pharmacy services directly into the home BLOOMINGTON, Minn., May 27, 2026 (GLOBE NEWSWIRE) -- Ōmcare and PharMerica are proud to announce the launch of the [...]
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05/2026
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-initiated study in [...]
Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics
27/05/2026
Company has now raised $6 million since founding to advance mRNA-based therapeutics designed to turn tumor cells into immune-activating cells SAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Reprogram Biosciences, a [...]
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
27/05/2026
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, [...]
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
27/05/2026
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: [...]
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
27/05/2026
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability [...]

Pages